Velaglucerase alfa

Johannes M. F. G. Aerts; Uma Yasothan; Peter Kirkpatrick

doi:10.1038/nrd3311

Velaglucerase alfa

Johannes M. F. G. Aerts
, Uma Yasothan
, Peter Kirkpatrick

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010

Original language	English
Pages (from-to)	837-838
Journal	Nature reviews. Drug discovery
Volume	9
Issue number	11
DOIs	https://doi.org/10.1038/nrd3311
Publication status	Published - 2010

Access to Document

10.1038/nrd3311

Cite this

@article{24b02fd5a964486aa1b5f1ec98191270,

title = "Velaglucerase alfa",

abstract = "In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010",

author = "Aerts, \{Johannes M. F. G.\} and Uma Yasothan and Peter Kirkpatrick",

year = "2010",

doi = "10.1038/nrd3311",

language = "English",

volume = "9",

pages = "837--838",

journal = "Nature reviews. Drug discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Velaglucerase alfa

AU - Aerts, Johannes M. F. G.

AU - Yasothan, Uma

AU - Kirkpatrick, Peter

PY - 2010

Y1 - 2010

N2 - In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010

AB - In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010

U2 - 10.1038/nrd3311

DO - 10.1038/nrd3311

M3 - Article

C2 - 21030995

SN - 1474-1776

VL - 9

SP - 837

EP - 838

JO - Nature reviews. Drug discovery

JF - Nature reviews. Drug discovery

IS - 11

ER -

Velaglucerase alfa

Abstract

Access to Document

Fingerprint

Cite this